Toronto, Ontario – TheNewswire - 13 May, 2026 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, is pleased to announce the following appointments, effective immediately: Zachary T. Stadnyk, former TSX Life Sciences Lead and a biotech capital markets executive, has been appointed to the Company’s Board of Directors (the “Board”), and Natalia L. Butterworth, Director, Corporate Secretarial and Governance at ARO Consulting Inc., has been appointed Corporate Secretary of the Company.

 

Mr. Stadnyk brings more than 15 years of experience across biotechnology, capital markets, and public company leadership, including serving as Head of Life Sciences at the TSX and TSXV, where he advised biotech issuers, boards and institutional investors on public listings, capital formation and strategic positioning, with deep experience in public market execution. Over the course of his career, he has led and supported over $100 million in institutional financings, contributed to strategic transactions including the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth, and advised public companies across the biotech, healthcare and AI sectors.

 

Ms. Butterworth is a seasoned corporate governance professional with over 15 years of experience supporting public and private companies in governance and regulatory compliance across multiple jurisdictions, spanning the pharmaceutical, technology, and finance sectors. Based in British Columbia, both appointees strengthen Helix’s Canadian capital markets and governance expertise as the Company advances its capital markets strategy, including preparations for a planned Nasdaq listing through the Multijurisdictional Disclosure System (“MJDS”).

 

“As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma. “Zach brings a wealth of experience across biotechnology financing, public markets and strategic transactions, while Natalia adds strong governance and corporate secretarial expertise. These appointments come at an important time for Helix as we finalize the clinical protocol for L-DOS47 and actively prepare for a Nasdaq listing under the MJDS, including ongoing audit, governance, and capital markets readiness initiatives.”

 

Zachary Stadnyk, Director of Helix BioPharma, added, “I am excited to join Helix at such a pivotal stage in its development. The Company’s differentiated approach to addressing the tumor microenvironment and its clear path toward a Nasdaq listing creates a compelling opportunity. I look forward to supporting the team in advancing its capital markets strategy and unlocking value for its shareholders.”  

 

In connection with the Company’s ongoing capital markets and governance initiatives, Helix also announces that it is in the process of relocating its registered and records office from Toronto, Ontario to Vancouver, British Columbia. The proposed move aligns with the strengthening of the Company’s governance and capital markets infrastructure as Helix advances its Nasdaq uplisting strategy under the MJDS framework.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

 

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, please visit: https://www.helixbiopharma.com/

 

For more information, please contact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2700

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Thomas Mehrling, MD, PhD, Chief Executive Officer

corporate@helixbiopharma.com

  

Forward-Looking Statements and Risks and Uncertainties

 

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to DOS47, LR 09 and GEMCEDA. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

 

Forward-looking statements are necessarily based on a number of estimates and assumptions that the Company considered appropriate and reasonable as of the date such information is given, including but not limited to the assumptions regarding the implied benefits of the transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the risk that the Company's assumptions on which its forward-looking statements are based may not be accurate; the ability of the Company to capitalize on the potential benefits of the transactions; and the risk factors disclosed in the Company's periodic reports publicly filed and available on its SEDAR+ profile at www.sedarplus.ca. No assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur. There is no assurance that the proposed transactions will be completed in accordance with its terms or at all. The forward-looking statements contained in this news release are made as of the date of this announcement and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

   

_________________